Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

About this update from Arrowhead Pharmaceuticals, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1609,"height":335,"url":"https://media.zenfs.com/en/business-wire.com/5434282b5d031be0616620f8b0eb5d77"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g8Ndo.Nv3_s9hCVb0CQr_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5434282b5d031be0616620f8b0eb5d77","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.x0lcD2TNUDoVUigoDFoEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5434282b5d031be0616620f8b0eb5d77","width":1200,"height":250}},"lazy":false},{"type":"text","content":"- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide alone","length":216,"tagName":"p","attribs":{}},{"type":"text","content":"- ARO-INHBE drove robust fat reduction including -23.2% visceral fat, -15.4% total fat, and -76.7% liver fat reduction, representing an approximately three-fold improvement in all these measures versus tirzepatide alone in obese diabetic patients","length":246,"tagName":"p","attribs":{}},{"type":"text","content":"- ARO-INHBE monotherapy achieved mean visceral fat reduction of -9.9% (single dose, week 16) and -15.6% placebo adjusted (two doses, week 24) with single dose treatment increasing lean muscle tissue by 3.6 %","length":207,"tagName":"p","attribs":{}},{"type":"text","content":"- ARO-ALK7 is the first RNAi-therapeutic to show knockdown in humans of an adipocyte expressed gene and achieved a mean reduction of -88% in ALK7 mRNA with a maximum reduction of -94%","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"- ARO-ALK7 monotherapy achieved a -14.1% (single dose, week 8) placebo adjusted visceral fat reduction","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"- Company hosting a virtual KOL webinar today, January 6, 2026, at 11:30 am EST to discuss results","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"PASADENA, Calif., January 06, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical ...

More updates from Arrowhead Pharmaceuticals, Inc.